Novel therapeutic targets in non-small cell lung cancer
M Alamgeer, V Ganju, DN Watkins - Current opinion in pharmacology, 2013 - Elsevier
Oncogenic driver mutations frequently occur in lung cancer and play role in carcinogenesis.
These mutations are usually associated with distinct clinical and histological features and …
These mutations are usually associated with distinct clinical and histological features and …
[HTML][HTML] The evolution of therapies in non-small cell lung cancer
V Boolell, M Alamgeer, DN Watkins, V Ganju - Cancers, 2015 - mdpi.com
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
M Shea, DB Costa… - Therapeutic advances in …, 2016 - journals.sagepub.com
Precision oncology is now the evidence-based standard of care for the management of
many advanced non-small cell lung cancers (NSCLCs). Expert consensus has defined …
many advanced non-small cell lung cancers (NSCLCs). Expert consensus has defined …
Targeted therapies for non–small cell lung cancer: an evolving landscape
SK Pal, RA Figlin, K Reckamp - Molecular cancer therapeutics, 2010 - AACR
Over the past decade, a multitude of targeted agents have been explored in the treatment of
advanced non–small cell lung cancer (NSCLC). Thus far, two broad classes of agents have …
advanced non–small cell lung cancer (NSCLC). Thus far, two broad classes of agents have …
[HTML][HTML] Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
BA Chan, BGM Hughes - Translational lung cancer research, 2015 - ncbi.nlm.nih.gov
In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …
Targeted therapies for non-small cell lung cancer
WCM Dempke, T Suto, M Reck - Lung cancer, 2010 - Elsevier
Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all cases of lung
cancer, and it is the most common cause of death in men and second only to breast cancer …
cancer, and it is the most common cause of death in men and second only to breast cancer …
[PDF][PDF] NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance
RC Black, H Khurshid - Rhode Island medical journal, 2015 - rimed.org
Lung cancer is the most common malignancy in the US and causes the most cancer-related
deaths. Non-smallcell lung carcinoma (NSCLC) accounts for the majority of cases. NSCLC …
deaths. Non-smallcell lung carcinoma (NSCLC) accounts for the majority of cases. NSCLC …
New targets in lung cancer (excluding EGFR, ALK, ROS1)
A Russo, AR Lopes, MG McCusker… - Current Oncology …, 2020 - Springer
Abstract Purpose of Review Over the last two decades, the identification of targetable
oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung …
oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung …
[HTML][HTML] Advanced-stage non–small cell lung cancer: advances in thoracic oncology 2018
In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of
immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of …
immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of …
Targeted therapy for non-small-cell lung cancer: past, present and future
PM Forde, DS Ettinger - Expert review of anticancer therapy, 2013 - Taylor & Francis
Therapy for advanced non-small-cell lung cancer has developed significantly with new
awareness of histologic subtype as an important factor in guiding treatment and the …
awareness of histologic subtype as an important factor in guiding treatment and the …